NervGen Pharma (NASDAQ:NGEN) Posts Quarterly Earnings Results, Beats Estimates By $999.07 EPS

NervGen Pharma (NASDAQ:NGEN) posted its quarterly earnings data on Friday. The company reported $999.00 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $999.07, reports.

NervGen Pharma Stock Performance

NASDAQ:NGEN traded down $0.14 during trading hours on Friday, reaching $3.57. 407,740 shares of the company’s stock were exchanged, compared to its average volume of 168,767. NervGen Pharma has a 12 month low of $1.50 and a 12 month high of $6.30.

Analysts Set New Price Targets

NGEN has been the subject of a number of research reports. HC Wainwright upgraded shares of NervGen Pharma to a “strong-buy” rating in a report on Tuesday, April 28th. Zacks Research upgraded shares of NervGen Pharma to a “hold” rating in a report on Wednesday, April 29th. Stifel Nicolaus upgraded shares of NervGen Pharma to a “strong-buy” rating in a report on Thursday, April 23rd. Weiss Ratings initiated coverage on shares of NervGen Pharma in a report on Friday, April 24th. They set a “sell (d-)” rating for the company. Finally, Wall Street Zen cut shares of NervGen Pharma from a “sell” rating to a “strong sell” rating in a report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.00.

NervGen Pharma Company Profile

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.